Literature DB >> 16636174

Physiological and clinical consequences of relief of right ventricular outflow tract obstruction late after repair of congenital heart defects.

Louise Coats1, Sachin Khambadkone, Graham Derrick, Shankar Sridharan, Silvia Schievano, Bryan Mist, Rod Jones, John E Deanfield, Denis Pellerin, Philipp Bonhoeffer, Andrew M Taylor.   

Abstract

BACKGROUND: Right ventricular outflow tract obstruction (RVOTO) is a common problem after repair of congenital heart disease. Percutaneous pulmonary valve implantation (PPVI) can treat this condition without consequent pulmonary regurgitation or cardiopulmonary bypass. Our aim was to investigate the clinical and physiological response to relieving RVOTO. METHODS AND
RESULTS: We studied 18 patients who underwent PPVI for RVOTO (72% male, median age 20 years) from a total of 93 who had this procedure for various indications. All had a right ventricular outflow tract (RVOT) gradient >50 mm Hg on echocardiography without important pulmonary regurgitation (less than mild or regurgitant fraction <10% on magnetic resonance imaging [MRI]). Cardiopulmonary exercise testing, tissue Doppler echocardiography, and MRI were performed before and within 50 days of PPVI. PPVI reduced RVOT gradient (51.4 to 21.7 mm Hg, P<0.001) and right ventricular systolic pressure (72.8 to 47.3 mm Hg, P<0.001) at catheterization. Symptoms and aerobic (25.7 to 28.9 mL.kg(-1).min(-1), P=0.002) and anaerobic (14.4 to 16.2 mL.kg(-1).min(-1), P=0.002) exercise capacity improved. Myocardial systolic velocity improved acutely (tricuspid 4.8 to 5.3 cm/s, P=0.05; mitral 4.7 to 5.5 cm/s, P=0.01), whereas isovolumic acceleration was unchanged. The tricuspid annular velocity was not maintained on intermediate follow-up. Right ventricular end-diastolic volume (99.9 to 89.7 mL/m2, P<0.001) fell, whereas effective stroke volume (43.7 to 48.3 mL/m2, P=0.06) and ejection fraction (48.0% to 56.8%, P=0.01) increased. Left ventricular end-diastolic volume (72.5 to 77.4 mL/m2, P=0.145), stroke volume (45.3 to 50.6 mL/m2, P=0.02), and ejection fraction (62.6% to 65.8%, P=0.03) increased.
CONCLUSIONS: PPVI relieves RVOTO, which leads to an early improvement in biventricular performance. Furthermore, it reduces symptoms and improves exercise tolerance. These findings have important implications for the management of this increasingly common condition.

Entities:  

Mesh:

Year:  2006        PMID: 16636174     DOI: 10.1161/CIRCULATIONAHA.105.591438

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  21 in total

1.  Short- and medium-term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US melody valve trial.

Authors:  Doff B McElhinney; William E Hellenbrand; Evan M Zahn; Thomas K Jones; John P Cheatham; James E Lock; Julie A Vincent
Journal:  Circulation       Date:  2010-07-19       Impact factor: 29.690

2.  Patient-specific reconstructed anatomies and computer simulations are fundamental for selecting medical device treatment: application to a new percutaneous pulmonary valve.

Authors:  Claudio Capelli; Andrew M Taylor; Francesco Migliavacca; Philipp Bonhoeffer; Silvia Schievano
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2010-06-28       Impact factor: 4.226

Review 3.  Cardiac imaging: MR or CT? Which to use when.

Authors:  Andrew M Taylor
Journal:  Pediatr Radiol       Date:  2008-06

4.  Percutaneous pulmonic valve implantation.

Authors:  Arun Kumar; Clifford Kavinsky; Zahid Amin; Ziyad M Hijazi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-12

5.  Early echocardiographic changes after percutaneous implantation of the Edwards SAPIEN transcatheter heart valve in the pulmonary position.

Authors:  Shahryar M Chowdhury; Ziyad M Hijazi; John Rhodes; Saibal Kar; Raj Makkar; Michael Mullen; Qi-Ling Cao; Lydia King; Jodi Akin; Girish Shirali
Journal:  Echocardiography       Date:  2013-02-22       Impact factor: 1.724

6.  Changes in speckle tracking echocardiography measures of ventricular function after percutaneous implantation of the Edwards SAPIEN transcatheter heart valve in the pulmonary position.

Authors:  Shahryar M Chowdhury; Ziyad M Hijazi; John F Rhodes; Saibal Kar; Raj Makkar; Michael Mullen; Qi-Ling Cao; Lazar Mandinov; Jason Buckley; Nicholas P Pietris; Girish S Shirali
Journal:  Echocardiography       Date:  2014-07-22       Impact factor: 1.724

Review 7.  Valvular heart disease in congenital heart disease: a narrative review.

Authors:  Joshua M Saef; Joanna Ghobrial
Journal:  Cardiovasc Diagn Ther       Date:  2021-06

Review 8.  Will catheter interventions replace surgery for valve abnormalities?

Authors:  Michael L O'Byrne; Matthew J Gillespie
Journal:  Curr Opin Cardiol       Date:  2014-01       Impact factor: 2.161

9.  Percutaneous pulmonary and tricuspid valve implantations: An update.

Authors:  Robert Wagner; Ingo Daehnert; Philipp Lurz
Journal:  World J Cardiol       Date:  2015-04-26

10.  Effective transcatheter valve implantation after pulmonary homograft failure: a new perspective on the Ross operation.

Authors:  Johannes Nordmeyer; Philipp Lurz; Victor T Tsang; Louise Coats; Fiona Walker; Andrew M Taylor; Sachin Khambadkone; Marc R de Leval; Philipp Bonhoeffer
Journal:  J Thorac Cardiovasc Surg       Date:  2009-04-25       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.